Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28856641 | 0.91 | SLC7A5 (0.47) | SLC7A5ANPEPRNPEPDNPEPMME | |
| SCHEMBL2489676 | 0.91 | SLC7A5 (0.47) | SLC7A5ANPEPRNPEPDNPEPMME | |
| SCHEMBL2491591 | 0.91 | SLC7A5 (0.47) | SLC7A5ANPEPRNPEPDNPEPMME | |
| SCHEMBL196338 | 0.88 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPMME | |
| SCHEMBL76796 | 0.88 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPMME | |
| SCHEMBL700933 | 0.88 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPMME | |
| SCHEMBL29783468 | 0.88 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPMME | |
| Hydrochloric Acid SCHEMBL76795 | 0.86 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPMME | |
| Hydrochloric Acid SCHEMBL355415 | 0.86 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPMME | |
| Hydrochloric Acid SCHEMBL353346 | 0.86 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2014291-B1 | Piperazinone compounds as anti-tumor and anti-cancer agents | UNIV YALE (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7763620-B2 | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | YALE UNIVERSITY (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1427418-B1 | PIPERAZINONE COMPOUNDS AS ANTI-TUMOR AND ANTI-CANCER AGENTS | UNIV YALE (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2014291-A2 | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | YALE UNIVERSITY (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080221123-A1 | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment | YALE UNIVERSITY | 2008-09-11 | — | — | US | disclosed |
| EP-1427418-A4 | PIPERAZINONE COMPOUNDS AS ANTI-TUMOR AND ANTI-CANCER AGENTS AND METHODS OF TREATMENT | UNIV YALE (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1427418-A2 | PIPERAZINONE COMPOUNDS AS ANTI-TUMOR AND ANTI-CANCER AGENTS AND METHODS OF TREATMENT | YALE UNIVERSITY (US) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003017939-A2 | PIPERAZINONE COMPOUNDS AS ANTI-TUMOR AND ANTI-CANCER AGENTS AND METHODS OF TREATMENT | YALE UNIVERSITY (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221123-A1 | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment | EP300, HDAC5, VHL | SLC7A5 4513/4885ANPEP 2132/4885RNPEP 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.